Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC14731 structure
    GC14731MTT
    CAS: 298-93-1
    纯度: >98.00% / >99.00%

    A cell-permeable and positively charged tetrazolium dye

  • GC14755 structure
    GC14755Inauhzin
    CAS: 309271-94-1
    纯度: >99.00%

    A selective SIRT1 inhibitor

  • GC14756 structure
    GC14756EI1
    CAS: 1418308-27-6
    纯度: >99.50%

    A selective inhibitor of EZH2

  • GC14791 structure
    GC14791F16
    CAS: 36098-33-6
    纯度: >98.00%

    A potential antitumor agent

  • GC14794 structure
    GC14794PF-06463922
    CAS: 1454846-35-5
    纯度: >99.50%

    PF-06463922是一种新型的、具有口服活性的ALK(IC 50 =15-113nM)和ROS1(K i s=0.025-0.7nM)双重抑制剂。

  • GC14800 structure
    GC14800ML 141
    CAS: 71203-35-5
    纯度: >98.50% / >98.00%

    An allosteric Cdc42 inhibitor

  • GC14815 structure
    GC14815GMX1778 (CHS828)
    CAS: 200484-11-3
    纯度: >99.00%

    GMX1778 (CHS828) 是一种特异性的烟酰胺磷酸核糖转移酶(NAMPT)抑制剂。

  • GC14817 structure
    GC14817Salermide
    CAS: 1105698-15-4
    纯度: >98.00%

    A sirtuin inhibitor

  • GC14847 structure
    GC14847Psoralidin
    CAS: 18642-23-4
    纯度: >98.00%

    A furanocoumarin with anti-cancer activity

  • GC14860 structure
    GC14860Oncrasin 1
    CAS: 75629-57-1
    纯度: >99.50%

    An anticancer agent

  • GC14882 structure
    GC14882Salinomycin
    CAS: 53003-10-4
    纯度: >98.00%

    A selective cancer stem cell inhibitor

  • GC14921 structure
    GC14921CPI-613 (Devimistat)
    CAS: 95809-78-2
    纯度: >98.00%

    An inhibitor of α-ketoglutarate dehydrogenase

  • GC14929 structure
    GC14929Monastrol
    CAS: 254753-54-3;329689-23-8
    纯度: >99.50%

    Monastrol是一种强效且具细胞通透性的有丝分裂驱动蛋白Eg5抑制剂,其 IC 50 为14μM。

  • GC14930 structure
    GC14930Benzbromarone
    CAS: 3562-84-3
    纯度: >99.50%

    An inhibitor of URAT1

  • GC14945 structure
    GC14945Sirtinol
    CAS: 410536-97-9
    纯度: >98.00%

    Inhibitor of sirtuin deacetylases

  • GC14957 structure
    GC14957OSI-930
    CAS: 728033-96-3
    纯度: >98.00%

    A dual inhibitor of Kit and VEGFR2

  • GC14987 structure
    GC14987GSK-3 Inhibitor IX (BIO)
    CAS: 667463-62-9
    纯度: >99.50%

    GSK-3 Inhibitor IX (BIO)是一种强效、选择性和可逆的糖原合成酶激酶-3(GSK-3)抑制剂,对GSK-3α/β的IC 50 值为5nM。

  • GC14998 structure
    GC14998Rocilinostat (ACY-1215)
    CAS: 1316214-52-4
    纯度: >98.00%

    A selective inhibitor of HDAC6

  • GC15002 structure
    GC15002Sodium Phenylbutyrate
    CAS: 1716-12-7
    纯度: >99.50%

    Sodium Phenylbutyrate是一种组蛋白去乙酰化酶(HDAC)抑制剂。

  • GC15022 structure
    GC15022Vandetanib (ZD6474)
    CAS: 443913-73-3
    纯度: >99.50%

    A multi-kinase inhibitor

  • GC15031 structure
    GC15031Rapamycin (Sirolimus)
    CAS: 53123-88-9
    纯度: >98.00% / >99.50%

    Rapamycin曾经被用作抗真菌抗生素。

  • GC15033 structure
    GC15033Azathioprine
    CAS: 446-86-6
    纯度: >99.50%

    An immunosuppressive purine analog

  • GC15047 structure
    GC15047PHA-793887
    CAS: 718630-59-2
    纯度: >98.00%

    A CDK inhibitor

  • GC15055 structure
    GC15055AZ 628
    CAS: 878739-06-1
    纯度: >99.50%

    A Raf kinase inhibitor